BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 25763208)

  • 1. Intravitreal clindamycin in the treatment of unresponsive zone one toxoplasmic chorioretinitis: a case report.
    Hosseini SM; Abrishami M; Mehdi Zadeh M
    Iran Red Crescent Med J; 2014 Nov; 16(11):e15428. PubMed ID: 25763208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravitreal clindamycin plus dexamethasone versus classic oral therapy in toxoplasmic retinochoroiditis: a prospective randomized clinical trial.
    Baharivand N; Mahdavifard A; Fouladi RF
    Int Ophthalmol; 2013 Feb; 33(1):39-46. PubMed ID: 23053769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravitreal Clindamycin as First-Line Therapy for Toxoplasmic Retinochoroiditis: A Case Series.
    Verma L; Thulasidas M; Gupta A
    Clin Ophthalmol; 2020; 14():4279-4285. PubMed ID: 33324033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravitreal clindamycin and dexamethasone for toxoplasmic retinochoroiditis.
    Kishore K; Conway MD; Peyman GA
    Ophthalmic Surg Lasers; 2001; 32(3):183-92. PubMed ID: 11371084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Local treatment of toxoplasmic retinochoroiditis with intravitreal clindamycin and dexamethasone.
    Zamora YF; Arantes T; Reis FA; Garcia CR; Saraceno JJ; Belfort R; Muccioli C
    Arq Bras Oftalmol; 2015; 78(4):216-9. PubMed ID: 26375334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravitreal clindamycin for toxoplasmic retinochoroiditis.
    Sobrin L; Kump LI; Foster CS
    Retina; 2007 Sep; 27(7):952-7. PubMed ID: 17891023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravitreal clindamycin and dexamethasone for zone 1 toxoplasmic retinochoroiditis at twenty-four months.
    Lasave AF; Díaz-Llopis M; Muccioli C; Belfort R; Arevalo JF
    Ophthalmology; 2010 Sep; 117(9):1831-8. PubMed ID: 20471684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Extensive toxoplasmic retinochoroiditis. Diagnostic and therapeutic management].
    Theaudin M; Bodaghi B; Cassoux N; Romand S; Le Mer Y; Lemaitre C; Fardeau C; Thulliez P; LeHoang P
    J Fr Ophtalmol; 2003 Nov; 26(9):921-7. PubMed ID: 14631276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Presumed toxoplasmic chorioretinitis: comparative study of treatment with pyrimethamine and sulfadiazine or clindamycin].
    Colin J; Harie JC
    J Fr Ophtalmol; 1989; 12(3):161-5. PubMed ID: 2695556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Intravitreal clindamycin injection in toxoplasma retinochoroiditis: About 9 cases in the ophthalmology department of the CHU de Bordeaux].
    Handaye-Dessus A; Gattoussi S; Korobelnik JF; Delyfer MN; Rougier MB
    J Fr Ophtalmol; 2021 Sep; 44(7):968-976. PubMed ID: 34247873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of a slow-release intravitreal clindamycin implant for the management of ocular toxoplasmosis.
    Jorge R; Coelho IN; Silva-Cunha A; Fernandes Cunha GM; Scott IU; Fialho SL; Furtado JM
    Am J Ophthalmol Case Rep; 2021 Jun; 22():101093. PubMed ID: 33981913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adverse drug reactions to treatments for ocular toxoplasmosis: a retrospective chart review.
    Iaccheri B; Fiore T; Papadaki T; Androudi S; Janjua S; Bhaila I; Stephen Foster C
    Clin Ther; 2008 Nov; 30(11):2069-74. PubMed ID: 19108794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clindamycin in the treatment of toxoplasmic retinochoroiditis.
    Lakhanpal V; Schocket SS; Nirankari VS
    Am J Ophthalmol; 1983 May; 95(5):605-13. PubMed ID: 6846454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Recurrent toxoplasmic retinochoroiditis after clindamycin treatment].
    Benzina Z; Chaabouni S; Hentati N; Trigui A; Chaabouni F; Ben Salah S; Khlif H; Feki J
    J Fr Ophtalmol; 2005 Nov; 28(9):958-64. PubMed ID: 16395222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toxoplasma gondii: an atypical presentation of toxoplasma as optic disc swelling and hemispherical retinal vein occlusion treated with intravitreal clindamycin.
    Wong R; dell'Omo R; Marino M; Hussein B; Okhravi N; Pavesio CE
    Int Ophthalmol; 2009 Jun; 29(3):195-8. PubMed ID: 18297246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Foveal reorganization after treatment of acute foveal toxoplasmic retinochoroiditis.
    Abrishami M; Hosseini SM; Momtahen S; Zamani G
    J Ophthalmic Inflamm Infect; 2021 Jun; 11(1):18. PubMed ID: 34151385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective randomized trial of trimethoprim/sulfamethoxazole versus pyrimethamine and sulfadiazine in the treatment of ocular toxoplasmosis.
    Soheilian M; Sadoughi MM; Ghajarnia M; Dehghan MH; Yazdani S; Behboudi H; Anisian A; Peyman GA
    Ophthalmology; 2005 Nov; 112(11):1876-82. PubMed ID: 16171866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized trial of intravitreal clindamycin and dexamethasone versus pyrimethamine, sulfadiazine, and prednisolone in treatment of ocular toxoplasmosis.
    Soheilian M; Ramezani A; Azimzadeh A; Sadoughi MM; Dehghan MH; Shahghadami R; Yaseri M; Peyman GA
    Ophthalmology; 2011 Jan; 118(1):134-41. PubMed ID: 20708269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravitreal clindamycin as a therapeutic alternative in severe ocular toxoplasmosis.
    Tabuenca Del Barrio L; Heras Mulero H; Mozo Cuadrado M; Fanlo Mateo P; Compains Silva E
    Arch Soc Esp Oftalmol (Engl Ed); 2019 Dec; 94(12):602-604. PubMed ID: 31607401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current treatment of ocular toxoplasmosis in immunocompetent patients: a network meta-analysis.
    Zhang Y; Lin X; Lu F
    Acta Trop; 2018 Sep; 185():52-62. PubMed ID: 29704469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.